MaaT Pharma schedules FDA Pre-IND for MaaT034
MaaT Pharma says it has scheduled an FDA Pre-IND meeting for MaaT034 in Oct 2026, focused on CMC. The company targets first-in-human study start in late 2027, pending regulatory clearance and funding.
MaaT Pharma said it has scheduled a CMC-focused FDA Pre-IND meeting in Oct 2026 for MaaT034, a microbiome therapy intended to be combined with PD-(L)1 inhibitors. The company said a first-in-human study could begin in late 2027, subject to regulatory clearance and funding.